Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

Summary

This phase I trial studies the side effects and the best dose of veliparib and dinaciclib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment. Veliparib and dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2011-11-11

Primary completion

2023-03-28

Completion

2026-08-02

Drugs

Indications